Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05296304
Other study ID # 21-501
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 16, 2022
Est. completion date March 2025

Study information

Verified date April 2024
Source Memorial Sloan Kettering Cancer Center
Contact Brandon Imber, MD, MS
Phone 631-212-6346
Email imberb@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin. The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Pathologically confirmed cutaneous T-cell lymphoma consistent with mycosis fungoides (MF) based on biopsy done or reviewed at MSKCC - Stage IB or higher MF per ISCL/EORTC criteria; concurrent diagnosis of Sézary syndrome permissible. Patients who have not had prior systemic therapies and refractory/relapsed patients are eligible. - Baseline mSWAT score of at least 10 - Stable topical steroids or systemic antipruritic agent (e.g. antihistamines, doxepin, GABA analogs) preceding study entry is permissible, but no new prescribed or over the counter topical or systemic anti-pruritics started post-enrollment - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Ability to provide informed consent Exclusion Criteria: - Any oral retinoid therapy for any indication within 3 weeks of the first dose of study drug - Prior TSEB (prior focal skin-directed RT acceptable) - Concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL) or another non-Hodgkin lymphoma - Concurrent diagnosis of additional non-skin malignancy - Pregnancy - Patients unwilling to use two forms of barrier contraception while taking study medication - Receipt of treatment with another investigational device or drug (at present or within 2 weeks of enrollment) - Familial hypertriglyceridemia or other medical conditions in which use of bexarotene would be contraindicated - High likelihood of protocol non-compliance (in opinion of investigator) - Systemic steroids within two weeks of first dose of study drug (patients on systemic steroids for non-disease related conditions will be permitted per investigator discretion) Prohibited concurrent medications - Gemfibrozil is contraindicated as may increase bexarotene concentrations - Bexarotene is a minor CYP3A4 substrate: avoid strong/moderate CYP3A4 inducers and inhibitors, if possible, but concomitant use is not a contraindication Bexarotene is a moderate CYP3A4 inducer: avoid concurrent administration with CYP3A4 sensitive substrates, for which minimal concentration changes may lead to therapeutic failures of the substrate (e.g. cyclosporine, tacrolimus, sirolimus, quinidine, fentanyl), if possible

Study Design


Intervention

Drug:
Bexarotene
Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
Radiation:
Total Skin Electron Beam (TSEB)
At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of radiation dermatitis grade 3+ as defined by number of patients who develop CTCAE, v. 5, grade 3+ toxicities at 1 month post-treatment. 1 month post-treatment
Secondary Overall skin response rate For patients with mycosis fungoides without blood involvement, the response criteria will be based upon modified international consensus guidelines.26 Specifically, skin response will be assessed by the Modified Severity Weighted Assessment Tool (mSWAT). For the purposes of this protocol, overall skin response will be considered to be either CR or PR. up to 82 days post-TSEB
See also
  Status Clinical Trial Phase
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Completed NCT00744991 - A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma Phase 2
Completed NCT00099593 - Immunization Against Tumor Cells in Sezary Syndrome Phase 2
Completed NCT02593045 - Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Phase 1
Recruiting NCT00779896 - Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Phase 1/Phase 2
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Withdrawn NCT00969085 - Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Phase 2
Completed NCT01728805 - Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Phase 3
Completed NCT00412997 - LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma Phase 1
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Recruiting NCT04296786 - Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study Phase 2
Recruiting NCT06285370 - A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy Phase 4
Completed NCT00071084 - Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. Phase 2
Completed NCT00896493 - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Phase 2
Terminated NCT00699296 - Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma Phase 2
Completed NCT02676778 - Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma Phase 2
Terminated NCT02061449 - Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma Phase 1
Completed NCT01134341 - Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1